Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Mastering Quantitative Quality Control: An In-Depth Guide to ISO 16628-14:2019
Essential Requirements and Best Practices for Control Materials in Medical Laboratories
Introduction to ISO 16628-14:2019
The ISO 16628 series addresses the quality management of control materials used in clinical laboratory testing and in vitro diagnostic test systems. Part 14 of this series, published in 2019, specifically provides detailed guidelines for the selection, use, and evaluation of control materials intended for quantitative analytical procedures. This standard complements broader quality management frameworks such as ISO 15189 and is indispensable for laboratories seeking to ensure the reliability, accuracy, and reproducibility of their quantitative test results. By standardizing the approach to internal quality control (IQC), ISO 16628-14:2019 helps laboratories detect analytical errors early, reduce patient risk, and maintain regulatory compliance.
Scope of the Standard
ISO 16628-14:2019 applies to all medical laboratories performing quantitative measurements on patient specimens, as well as manufacturers and suppliers of control materials. The standard covers:
- General principles for the use of control materials in quantitative procedures.
- Criteria for selecting appropriate control materials (e.g., matrix, concentration level, commutability).
- Procedures for establishing target values, evaluation of stability, and assigning control limits.
- Rules for interpreting control results and responding to out-of-control events.
- Documentation and record-keeping requirements.
It explicitly excludes qualitative tests, semi-quantitative methods, and procedures that rely solely on external quality assessment (EQA) without internal controls.
Technical Requirements
2.1 Selection of Control Materials
The standard mandates that control materials must be commutable with patient samples concerning the analyte and method. Laboratories must evaluate the matrix, storage stability, and available concentration levels. At least two levels (normal and abnormal) are recommended to cover the clinically relevant measuring interval.
2.2 Establishment of Target Values and Limits
For each control material, a target value (mean) must be determined through replicate measurements (e.g., 20 or more independent runs) following a dedicated replication protocol. Standard deviation (SD) or coefficient of variation (CV) is calculated to set control limits. The standard recommends using:
- Warning limits ± 2 SD
- Action limits ± 3 SD
These limits should be re‑evaluated periodically, especially after reagent lot changes, calibrator lot changes, or major instrument maintenance.
2.3 Frequency of Control Testing
The standard provides guidance on determining optimal QC frequency based on the patient risk and the performance characteristics of the procedure. Factors include the analytical error rate, the allowable total error, and the throughput of tests. The following table summarises recommended minimal frequencies:
| Testing Scenario | Minimum QC Frequency | Rationale |
|---|---|---|
| High-risk / stat tests (e.g., troponin, glucose) | Every batch or every 4 hours | Patient safety demands immediate error detection |
| Routine chemistry or immunoassays | At least once per run or per shift | Balance between error detection and operational efficiency |
| Low-volume or stable methods | After calibration, reagent lot change, and periodically (e.g., weekly) | Risk-based approach reduces waste without compromising quality |
Tip: Use a risk assessment tool (e.g., an FMEA) to establish or adjust your QC frequency. ISO 16628-14:2019 encourages a risk-based approach rather than a one-size-fits-all rule.
2.4 Interpretation of Control Results
The standard endorses the use of multi-rule QC procedures (e.g., Westgard rules) to interpret single and multiple control observations. Examples of rules applicable:
- 12s (warning rule)
- 13s (action rule – reject run)
- 22s (or R4s) for systematic error
- 41s, 10x for persistent bias
Out-of-control events must trigger documented investigation, corrective action, and, if necessary, repeating patient samples that might have been affected since the last acceptable QC result.
Implementation Highlights
Practical implementation of ISO 16628-14:2019 requires collaboration between laboratory management, quality officers, and technical staff. Key steps include:
- Selecting control materials: Procure third-party or manufacturer controls that match the analyte and sample type. Verify commutability for your specific method.
- Establishing QC protocols: Write standard operating procedures (SOPs) covering the entire QC process, from material reconstitution and storage to result review and corrective actions.
- Training personnel: Ensure all operators understand the QC rules, can identify violations, and know the escalation path.
- Leveraging middleware or LIS: Use software to auto‑interpret controls, flag out‑of‑range results, and integrate with corrective action logs.
- Periodic review: Store historical QC data and apply statistical quality control charts (Levey‑Jennings or Shewhart) to monitor long‑term performance.
Best Practice: Perform a yearly audit of your QC plan against ISO 16628-14:2019. Document any deviations and justify them based on patient risk and analytical performance.
Compliance and Audit Considerations
ISO 16628-14:2019 is not a standalone accreditation standard but is heavily referenced by ISO 15189 (Medical laboratories — Requirements for quality and competence). During accreditation audits, assessors will expect evidence of:
- Explicit risk‑based QC frequency for each quantitative procedure.
- Documented target values and control limits that have been verified on site.
- Records of control failures, investigations, and corrective actions.
- Validation data for control material commutability or at least an acknowledgment of its limitations.
- Policies for handling patient results when QC fails (including retesting and estimated bias).
Warning: Simply following manufacturer recommendations for QC frequency may not satisfy ISO 16628-14:2019. The standard expects laboratories to perform their own risk assessment and justify their chosen frequency.
Critical: Using control materials solely from the reagent manufacturer without independent evaluation of target values and limits can lead to systematic bias and increased risk of false accept/reject decisions.
Frequently Asked Questions
Q: Is ISO 16628-14:2019 mandatory for all medical laboratories?
A: While the standard itself is voluntary, its principles are embedded in many national accreditation schemes and are considered essential for demonstrating competent internal quality control under ISO 15189. Laboratories seeking ISO 15189 accreditation should adopt ISO 16628-14:2019 as a normative reference.
A: While the standard itself is voluntary, its principles are embedded in many national accreditation schemes and are considered essential for demonstrating competent internal quality control under ISO 15189. Laboratories seeking ISO 15189 accreditation should adopt ISO 16628-14:2019 as a normative reference.
Q: Can we use manufacturer-assigned target values directly?
A: The standard recommends that laboratories verify manufacturer values with their own measurement system (e.g., 20 independent runs) before adopting them. In cases where independent verification is not practical (e.g., rare controls), a documented risk assessment and periodic re‑evaluation are required.
A: The standard recommends that laboratories verify manufacturer values with their own measurement system (e.g., 20 independent runs) before adopting them. In cases where independent verification is not practical (e.g., rare controls), a documented risk assessment and periodic re‑evaluation are required.
Q: How often should control limits be updated?
A: Target values and SD should be recalculated at least once every six months, after instrument maintenance that affects measurement, after reagent or calibrator lot changes, and whenever the analytical performance shifts significantly. Control materials with expiry dates require shorter re‑evaluation intervals.
A: Target values and SD should be recalculated at least once every six months, after instrument maintenance that affects measurement, after reagent or calibrator lot changes, and whenever the analytical performance shifts significantly. Control materials with expiry dates require shorter re‑evaluation intervals.
Q: Does this standard apply to point‑of‑care testing (POCT)?
A: Yes, the general principles are applicable to POCT devices performing quantitative tests. The specific implementation (e.g., frequency of QC, choice of control materials) should be adapted to the device, its use environment, and patient risk.
A: Yes, the general principles are applicable to POCT devices performing quantitative tests. The specific implementation (e.g., frequency of QC, choice of control materials) should be adapted to the device, its use environment, and patient risk.